<DOC>
	<DOC>NCT02135666</DOC>
	<brief_summary>The purpose of this study is to assess the long-term persistence of immunity to hepatitis A and B in adults who were vaccinated 16-20 years earlier with the combined hepatitis A and hepatitis B vaccine, Twinrix.</brief_summary>
	<brief_title>Evaluation of the Long-term Hepatitis A and B Antibody Persistence in Healthy Adult Subjects, Primed 16 to 20 Years Earlier With GSK Biologicals' Combined Hepatitis A and B Vaccine, TwinrixÂ® (SB208127) in Study HAB-084 (208127/084)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol. A male or female who received two/three doses of Twinrix according to his/her group allocation in study HAB084 (208127/084), and received no further dose of any hepatitis A and/or B vaccine since then. Written informed consent obtained from the subject. Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immunemodifying drugs within six months prior to study entry. Inhaled and topical steroids are allowed. Administration of longacting immunemodifying drugs within six months prior to the study entry. Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a noninvestigational vaccine/product (pharmaceutical product or device). Administration of any hepatitis A and/or B vaccine at any time since completion of the primary vaccination series in HAB084 (208127/084) study, including a challenge dose of the study vaccine, as a part of the study procedures, during the longterm persistence phase. Documented history of hepatitis A or B disease since completion of the primary vaccination series in HAB084 (208127/084) study. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required). Administration of immunoglobulins within six months prior to study entry.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Twinrix</keyword>
	<keyword>Long-term follow-up</keyword>
	<keyword>Persistence</keyword>
	<keyword>Hepatitis A</keyword>
	<keyword>Antibody</keyword>
	<keyword>Immunity</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Combination vaccine</keyword>
	<keyword>Adult</keyword>
</DOC>